2026-2034年全球放射性藥物/核醫市場規模、佔有率、趨勢和成長分析報告

預計放射性藥物/核醫市場將從 2025 年的 217.8 億美元成長到 2034 年的 395.1 億美元，2026 年至 2034 年的複合年成長率為 6.84%。

全球放射性藥物/核醫市場持續穩定成長，這主要得益於核子醫學掃描術診斷技術在疾病診斷和治療中日益廣泛的應用。放射性藥物廣泛應用於腫瘤學、心臟病學和神經病學領域，用於精準成像和標靶治療。癌症和心血管疾病發生率的上升加速了對先進診斷工具的需求。 PET和SPECT等影像技術的進步正在提高診斷的準確性和早期檢測能力。

關鍵成長要素包括醫療基礎設施投資的增加和個人化醫療方法的廣泛應用。放射性同位素生產和標靶放射治療的技術創新正在擴大治療應用範圍。已開發地區人口老化顯著推高了市場需求，因為老年人更容易患慢性疾病。新型放射性藥物的監管核准進一步加速了市場擴張，並促進了製藥公司在研發方面的投入。

將診斷和治療相結合的治療診斷學（診斷-治療融合）方法的發展為未來帶來了光明的前景。迴旋加速器設施的擴建和分銷網路的改善將提高新興市場的可近性。研究機構和醫療服務提供者之間的合作有望加速創新。隨著精準癌症治療的進步，放射性藥物將成為標靶治療策略的關鍵，並有望在未來幾年推動其持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球放射性藥物/核醫市場：依應用領域分類

• 市場分析、洞察與預測
• 診斷
• 治療用途

第5章 全球放射性藥物/核醫市場：依來源分類

• 市場分析、洞察與預測
• 核子反應爐
• 迴旋加速器

第6章 全球放射性藥物/核醫市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 診斷中心
• 癌症研究機構
• 門診手術中心
• 其他

第7章 全球放射性藥物/核醫市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Novartis AG
  • Siemens Healthineers AG
  • Bayer AG
  • GE HealthCare
  • Lantheus
  • Curium
  • Jubilant Radiopharma
  • Eckert & Ziegler
  • Cardinal Health
  • Telix Pharmaceuticals Limited
  • Bracco
  • Lilly
  • AstraZeneca

The Radiopharmaceutical/Nuclear Medicine Market size is expected to reach USD 39.51 Billion in 2034 from USD 21.78 Billion (2025) growing at a CAGR of 6.84% during 2026-2034.

The Global Radiopharmaceutical/Nuclear Medicine Market has grown steadily with increasing utilization of nuclear imaging techniques for disease diagnosis and treatment. Radiopharmaceuticals are widely used in oncology, cardiology, and neurology for precise imaging and targeted therapy. Rising prevalence of cancer and cardiovascular diseases has accelerated demand for advanced diagnostic tools. Improvements in imaging technologies such as PET and SPECT have enhanced accuracy and early detection capabilities.

Key drivers include growing investments in healthcare infrastructure and expanding adoption of personalized medicine approaches. Technological innovations in radioisotope production and targeted radiotherapy have broadened therapeutic applications. Aging populations in developed regions contribute significantly to demand, as older individuals are more prone to chronic diseases. Regulatory approvals for novel radiopharmaceutical agents further stimulate market expansion, encouraging pharmaceutical companies to invest in research and development initiatives.

Future prospects are promising with the development of theranostic approaches that combine diagnosis and therapy. Expansion of cyclotron facilities and improved distribution networks will enhance accessibility in emerging markets. Collaborations between research institutions and healthcare providers are expected to accelerate innovation. As precision oncology advances, radiopharmaceuticals will likely become integral to targeted treatment strategies, driving sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Diagnostic
• Therapeutic

By Source

• Nuclear Reactors
• Cyclotrons

By End User

• Hospitals
• Diagnostic Centers
• Cancer Research Institutes
• Ambulatory Surgical Centers
• Others

COMPANIES PROFILED

• Novartis AG, Siemens Healthineers AG, Bayer AG, GE HealthCare, Lantheus, Curium, Jubilant Radiopharma, Eckert Ziegler, Cardinal Health, Telix Pharmaceuticals Limited, Bracco, Lilly, AstraZeneca

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Diagnostic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Nuclear Reactors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cyclotrons Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cancer Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Application
  • 7.2.2 By Source
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Application
  • 7.3.2 By Source
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Application
  • 7.4.2 By Source
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Application
  • 7.5.2 By Source
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Application
  • 7.6.2 By Source
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL RADIOPHARMACEUTICAL/NUCLEAR MEDICINE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis AG
  • 9.2.2 Siemens Healthineers AG
  • 9.2.3 Bayer AG
  • 9.2.4 GE HealthCare
  • 9.2.5 Lantheus
  • 9.2.6 Curium
  • 9.2.7 Jubilant Radiopharma
  • 9.2.8 Eckert & Ziegler
  • 9.2.9 Cardinal Health
  • 9.2.10 Telix Pharmaceuticals Limited
  • 9.2.11 Bracco
  • 9.2.12 Lilly
  • 9.2.13 AstraZeneca